CBOE (CBOE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Civeo (CVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Charter (CHTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

T. Rowe (TROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The company will take a restructuring charge of $160 million to $180 million for severance and other items.

Jim Cramer breaks down why he's keeping an eye on shares of AMD.

Here is our perspective on why Light & Wonder (LNW) stock merits attention as a value investment. It is presently trading approximately 32% lower than its 1-year peak and is also trading at a PS multiple that is below the average from the past 3 years.

JPMorgan Chase reportedly plans to allow its institutional clients around the world to use their Bitcoin and Ether holdings as collateral for loans. The program is set to be offered by the end of the year, Bloomberg reported Friday (Oct. 24), citing unnamed sources.

Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On October 23, Gilead announced that it will announce data on the switching of people with PBC from obeticholic acid to its 'rising star' Livdelzi at The Liver Meeting 2025.

UNH's Q3 results hinge on premium growth and Optum gains amid rising costs and margin pressure.

Lam Research's strong AI chip exposure and robust growth make it a more compelling buy than Amtech Systems, which continues to face mature node weakness.

PYPL's Q3 results hinge on transaction revenues, fueled by Venmo growth, new payment features and rising digital commerce trends.

After losing some value lately, a hammer chart pattern has been formed for Ocular Therapeutix (OCUL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

The mean of analysts' price targets for Amylyx Pharmaceuticals (AMLX) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 31.2% in Aura Minerals (AUGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

After reaching an important support level, AAON, Inc. (AAON) could be a good stock pick from a technical perspective. AAON recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

The mean of analysts' price targets for Cognizant (CTSH) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for Delta (DAL) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Dutch Bros (BROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.